Trials / Not Yet Recruiting
Not Yet RecruitingNCT07438405
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
An Open-label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-sponsored AMG 732 Studies and Are Primary Proptosis Non-responders or Who Relapsed During the Safety Follow-up
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 732 | AMG 732 will be administered SC. |
Timeline
- Start date
- 2026-04-14
- Primary completion
- 2028-01-29
- Completion
- 2028-07-14
- First posted
- 2026-02-27
- Last updated
- 2026-04-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07438405. Inclusion in this directory is not an endorsement.